Sensei Biotherapeutics, Inc. Stock Price, News & Analysis

Sensei Biotherapeutics (NASDAQ: SNSE) reported strong progress in Q1 2021, highlighting advancements in its ImmunoPhage™ platform and the VISTA program. The company has commenced patient dosing in a Phase 1/2 study of SNS-301 for squamous cell carcinoma, with data accepted for presentation at ASCO 2021. Sensei ended the quarter with $169.4 million in cash, ensuring funding through at least mid-2023. The recent IPO raised $152.6 million, which will support ongoing and future research initiatives.

Sensei Biotherapeutics (NASDAQ: SNSE) announced the appointment of Dr. Maura Gillison and Dr. Richard Ulevitch to its Immuno-Oncology Advisory Board. Dr. Gillison, an expert in head and neck cancers, and Dr. Ulevitch, a leader in innate immunity, bring extensive knowledge to the company's strategic direction. Their insights aim to enhance the potential of the ImmunoPhage™ platform and foster collaboration among advisors to drive advancements in cancer treatment. This move is seen as a step towards bolstering Sensei's capabilities in developing innovative immunotherapies.

Sensei Biotherapeutics announces the appointment of Dr. Jessie M. English to its Board of Directors, bringing over 20 years of oncology research and leadership experience. Her expertise will enhance the company's ability to develop next-generation immunotherapies, including its proprietary ImmunoPhage™ platform. Dr. English previously led Tilos Therapeutics, acquired by Merck, and has held significant roles in major biotech firms. This leadership change aims to strengthen Sensei's clinical programs and support its vision during a critical development phase.

Sensei Biotherapeutics reports a strong financial foundation following its successful upsized IPO in February 2021, raising approximately $152.6 million. The company expects to release substantial data from the ongoing Phase 1/2 study of SNS-301 for treating advanced head and neck cancer by year-end. In 2020, Sensei increased R&D expenses to $11.9 million and G&A expenses to $7.5 million, resulting in a net loss of $20.1 million. Sensei was also added to the Russell 2000 Index on March 22, 2021, reflecting its growing market presence.

Sensei Biotherapeutics (Nasdaq: SNSE) has been added to the Russell 2000® Index effective March 22, 2021. The Russell 2000® Index represents the small-cap segment of the U.S. equity market and is a key benchmark for investment managers and institutional investors, with approximately $9 trillion in assets benchmarked against the Russell U.S. Indexes.

This inclusion offers Sensei Biotherapeutics enhanced visibility and potential access to a broader range of investors and index funds.

Sensei Biotherapeutics, a clinical-stage immunotherapy company, announced that CEO John Celebi will present at the Oppenheimer 31st Annual Virtual Healthcare Conference on March 16, 2021, at 9:20 a.m. ET. A live webcast of the presentation will be available on the company's website, with an archived version accessible for 90 days post-presentation.

Sensei Biotherapeutics focuses on developing next-generation immunotherapies, including its advanced therapy SNS-301, targeting tumor-associated antigens.

Sensei Biotherapeutics announced the closing of its initial public offering of 7,000,052 shares on February 8, 2021, with an additional 1,030,243 shares issued via an underwriter option on February 10, 2021. Priced at $19.00 per share, the gross proceeds totaled approximately $152.6 million, all from shares offered by Sensei. The company's stock trades on the Nasdaq Global Market under the ticker SNSE. Citigroup, Piper Sandler & Co., and Berenberg led the underwriting.

Cambrian Biopharma has successfully raised $60 million in private financing aimed at developing therapeutics to combat aging-related diseases. This funding coincides with the IPO of its portfolio company, Sensei Biotherapeutics (NASDAQ: SNSE), which began trading on February 4 and raised approximately $133 million in gross proceeds. Cambrian operates under a unique hub-and-spoke model to foster multiple drug discovery initiatives, targeting the 'Nine Hallmarks of Aging' through innovative therapies in fields like immunology and genomics.

Sensei Biotherapeutics has announced an upsized initial public offering (IPO) of 7,000,052 shares at $19.00 each, aiming to raise approximately $133 million. The shares will trade on Nasdaq under the ticker symbol SNSE starting February 4, 2021. Underwriters have an option to purchase an additional 1,050,007 shares. The offering is anticipated to close on February 8, 2021, pending market conditions. Sensei is known for its proprietary ImmunoPhage™ platform, which targets cancer and infectious diseases through innovative immunotherapy.